The Performance of Human Papillomavirus High-Risk DNA Testing in the Screening and Diagnostic Settings
Open Access
- 1 October 2008
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 17 (10) , 2865-2871
Abstract
Objective: We sought to evaluate the performance of the human papillomavirus high-risk DNA test in patients 30 years and older. Materials and Methods: Screening (n = 835) and diagnosis (n = 518) groups were defined based on prior Papanicolaou smear results as part of a clinical trial for cervical cancer detection. We compared the Hybrid Capture II (HCII) test result with the worst histologic report. We used cervical intraepithelial neoplasia (CIN) 2/3 or worse as the reference of disease. We calculated sensitivities, specificities, positive and negative likelihood ratios (LR+ and LR−), receiver operating characteristic (ROC) curves, and areas under the ROC curves for the HCII test. We also considered alternative strategies, including Papanicolaou smear, a combination of Papanicolaou smear and the HCII test, a sequence of Papanicolaou smear followed by the HCII test, and a sequence of the HCII test followed by Papanicolaou smear. Results: For the screening group, the sensitivity was 0.69 and the specificity was 0.93; the area under the ROC curve was 0.81. The LR+ and LR− were 10.24 and 0.34, respectively. For the diagnosis group, the sensitivity was 0.88 and the specificity was 0.78; the area under the ROC curve was 0.83. The LR+ and LR− were 4.06 and 0.14, respectively. Sequential testing showed little or no improvement over the combination testing. Conclusions: The HCII test in the screening group had a greater LR+ for the detection of CIN 2/3 or worse. HCII testing may be an additional screening tool for cervical cancer in women 30 years and older. (Cancer Epidemiol Biomarkers Prev 2008;17(10):2865–71)Keywords
This publication has 10 references indexed in Scilit:
- Maximizing the diversity of participants in a phase II clinical trial of optical technologies to detect cervical neoplasiaGynecologic Oncology, 2007
- Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical CancerNew England Journal of Medicine, 2007
- Diagnostic accuracy of human papillomavirus testing in primary cervical screening: A systematic review and meta-analysis of non-randomized studiesGynecologic Oncology, 2007
- Kappa statistics to measure interrater and intrarater agreement for 1790 cervical biopsy specimens among twelve pathologists: Qualitative histopathologic analysis and methodologic issuesGynecologic Oncology, 2005
- Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: Results from a multicenter study in IndiaInternational Journal of Cancer, 2004
- Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screeningBMJ, 2003
- A Thin-Layer, Liquid-Based Pap Test for Mass Screening in an Area of China with a High Incidence of Cervical CarcinomaActa Cytologica, 2003
- 2001 Consensus Guidelines for the Management of Women with Cervical Cytological AbnormalitiesJournal of Lower Genital Tract Disease, 2002
- Adjunctive testing for cervical cancer in low resource settings with visual inspection, HPV, and the Pap smearInternational Journal of Gynecology & Obstetrics, 2001
- Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric ApproachBiometrics, 1988